Results 81 to 90 of about 50,884 (170)

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania

Journal of Cardiovascular Emergencies, 2019
Background: Ferric carboxymaltose (FCM) treatment in case of iron deficient (ID) patients with chronic heart failure (CHF) has shown great promise according to the findings of recent studies in improvement of symptoms and quality of life, New York Heart ...
Lorenzovici László, Székely Andrea, Farkas-Ráduly Szabolcs, Jitaru Ciprian, Csanádi Marcell   +4 more
doaj   +1 more source

Expert Consensus on the Significance of Intravenous Iron using Ferric Carboxymaltose Perioperatively and in Elective Major Orthopedic Surgeries

Anemia has emerged as a significant healthcare crisis in India and often remains undiagnosed, with broad implications across all age groups. Iron deficiency remains the most important and correctable cause of anemia in our country.
Sachin Suryawanshi, Miten Sheth, Punit Jain, Surendar Singh Bava, Swarnendu Samanta, Attique Vasdev, Anand Galagali, Satish Sonar, Prashant Tonape, Ketan Kulkarni, Atul Panghate, Mohan Desai, K R Prathap Kumar, Ashraf Shaikh, Santhosh Shetty, Ashish Arbat   +15 more
core   +1 more source

Safety and efficacy of ferric carboxymaltose in children and adolescents with iron deficiency anemia

, 2017
Safety and efficacy of ferric carboxymaltose in children and adolescents with iron deficiency ...
Mantadakis, Elpis, Elpis Mantadakis, Jelena Roganovic, Roganović, Jelena   +3 more
core   +1 more source

Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron-deficiency anaemia: a Phase II single-arm study

, 2021
BACKGROUND: Ferric carboxymaltose is increasingly utilised to treat iron deficiency and is usually diluted in saline and administered as an intravenous infusion over 15 min.
Bennett, A, van Dam, M, Indran, T, Gilbertson, M, Dev, A, Chunilal, S, Coughlin, E, Pasricha, SR, Opat, S   +8 more
core   +1 more source

Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.

PLoS ONE, 2015
BackgroundThere is a significant clinical need for effective treatment of iron deficiency. A number of compounds that can be administered intravenously have been developed.
James R Connor, Xuesheng Zhang, Anne M Nixon, Becky Webb, Joseph R Perno   +4 more
doaj   +1 more source

Iron Deficiency in Heart Failure: Cellular Mechanisms and Therapeutic Implications

Journal of Cardiovascular Development and Disease
Iron deficiency (ID) is a prevalent comorbidity in heart failure (HF), affecting 37–75% of patients and contributing significantly to symptom burden and adverse outcomes independent of anemia status.
Anastasios Tsarouchas, Vassilios P. Vassilikos, Dimitrios Mouselimis, Christodoulos E. Papadopoulos, Dimitrios Tachmatzidis, Aikaterini Vassilikou, Constantinos Bakogiannis   +6 more
doaj   +1 more source

AN OVERVIEW OF BENEFITS AND SIDE EFFECTS OF CARBOXYMALTOSE INJECTION [PDF]

, 2022
Iron deficiency is widespread in many medical problems. Ferric carboxymaltose is a new stable iron preparation that can be given in single infusions over short time intervals. Between July and October 2022, a narrative literature review was conducted for
Nabil Saad Al-saedi, Badr Moriziq Al-solami, Mohamed Abdullah Garhady, Khairia Mohamed Kamli, Maha Hassan Hassan Ogdi, Mohammed Omar Al-zahrani, Habeeb Zaid Al-amri, Waheed mohamedrashad Felimban, Abdullah Hasan Al-homrani, Ahmed Hamed Al-majnoni
core  

Osteomalacia Following Iron Infusion Therapy in a Patient With Rendu‐Osler‐Weber Syndrome: F‐18‐FDG PET/CT Discrimination of a Stress Fracture in the Setting of a Musculoskeletal Tumor Mimic

Clinical Case Reports
This case report highlights a rare occurrence of osteomalacia induced by hypophosphatemia secondary to ferric carboxymaltose (FCM) therapy in a patient with hereditary hemorrhagic telangiectasia (HHT, or Rendu‐Osler‐Weber syndrome).
Ioannis S. Vasios, Pipitsa N. Valsamaki, Konstantinos Tilkeridis, Savvas Deftereos, Efthymios Iliopoulos   +4 more
doaj   +1 more source

Novel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure

JACC: Advances
Background: Worsening heart failure (WHF) challenges health care with frequent rehospitalizations and reduced quality of life for patients. Despite therapeutic advances, high rehospitalization risks highlight the urgent need for new treatments ...
Ivna G.C.V. Lima, MD, Jairo T. Nunes, MD, Lucas C. Godoy, MD PhD, Michael McDonald, MD, Edimar A. Bocchi, MD, PhD   +4 more
doaj   +1 more source

Hypocalcemia and Hypophosphatemia following Concurrent Denosumab Injection and Ferric Carboxymaltose Infusion in a Patient with Normal Renal Function

Case Reports in Endocrinology
Hypocalcemia following denosumab administration is well described. Hypophosphatemia following an intravenous iron infusion is an increasingly recognized adverse effect.
Naomi Szwarcbard, Chloe Dawson, Lai-Ming Kathleen Pak, Kathryn L. Hackman   +3 more
doaj   +1 more source